Why prevention screening is the cleanest AI opportunity nobody is building for

Prevention screening has the most evidence, the clearest workflow, the highest patient impact, and the most measurable outcome. And it's barely getting a slide at the conference. Why the field is chasing diagnosis when the leverage is upstream.

Everyone wants to put AI on the hard problems: diagnostic imaging, clinical decision support, ambient documentation — the visible, high-prestige bottlenecks. But the cleanest near-term opportunity is hiding in the most unglamorous corner of the encounter: prevention screening, and the follow-up that's supposed to come after it.

Here's the case.

The data is already structured and the action is already defined

Diagnostic AI has to reason from messy, ambiguous inputs toward a contested conclusion. Prevention screening doesn't. The eligibility logic is mostly deterministic — age, risk factors, prior findings, last-completed date. The recommended action is codified in guidelines: Fleischner Society criteria for lung nodules, USPSTF screening eligibility, the CMS quality set. You're not asking AI to be brilliant; you're asking it to close the gap between "this patient has a finding that warrants follow-up" and "the follow-up actually gets ordered" — reliably, at every encounter, without a human having to remember.

The failure mode isn't catastrophic — it's silent

A missed screening flag doesn't throw an error. No alert fires in the EHR. The failure is silent, and it plays out as a chain of small non-events spread across years.

Take one concrete illustration — lung cancer — because the connectivity fracture there is so well documented. It's the leading cause of cancer death in the United States, yet only about 6% of high-risk people are screened.¹ And most lung nodules aren't found by screening at all. They're found incidentally, on scans ordered for something else entirely.² The data almost always exists before anyone acts on it.

Picture the failure first. A 56-year-old comes into the ED with chest pain. A CT rules out the blood clot she was worried about — but the radiologist notes something incidental: a small lung nodule, unrelated to why she came in. She's discharged for the chest pain, the finding lives in a report in one system, and nothing connects it to a follow-up order. Half to two-thirds of incidental nodules never receive guideline-adherent follow-up — not because anyone decided against it, but because the tracking is manual: inboxes, spreadsheets, and broken handoffs between the radiologist, the ED, and a primary care team that may not exist yet.³ The nodule keeps growing. When it resurfaces, it's distant-stage disease, where five-year survival is about 8%.¹

Now rewind, and let the system do what it should. Same ED visit, same CT, same nodule — but an agentic layer reads that report the moment it's filed, recognizes the nodule, weighs it against her history, and routes her into guideline-based follow-up. It gets tracked. It turns out to be an early, localized cancer, treated while five-year survival is still around 63%.¹ The most consequential thing that happened to her was a flag firing on a report no one was reading for that purpose. Same scan, same patient — the entire difference is whether anything connected the finding to the next step.

This is the part most of us don't have to imagine. We've watched it happen to a parent, a colleague, a friend — the diagnosis that arrived "out of nowhere," which usually means it arrived years after a finding that was already sitting in a chart, unconnected to anyone who would act on it.

The gap is almost never a knowledge gap. The scan already saw it. What failed was the connective tissue.

And here's why it belongs in an engineering conversation, not only a clinical one: the radiologist saw the nodule and documented it. The data already knew. What failed was the connective tissue — the finding never reached the workflow moment where it could become a follow-up order, and no one confirmed the loop closed. That's not a hard AI problem. It's a high-volume, low-drama coordination problem with a forgiving risk profile and an enormous payoff — exactly the kind of work that's safe to automate and worth automating. And it isn't hypothetical: health systems are already pointing AI at every radiology report, surfacing the incidental findings, and routing patients into follow-up — detecting several times more early-stage cancers than screening alone.^4,5 The reason to build for it isn't that it's clever. It's that the cost of not building for it is measured in distant-stage diagnoses the data already knew how to prevent.

It maps cleanly onto value-based economics

Prevention and early detection are where the quality measures, the closed care gaps, and the downstream cost avoidance all converge. Catching disease at a localized stage isn't only better medicine — it's a stage-shift that keeps patients in-network for curative-intent care, drives appropriate downstream volume, and avoids the cost of late-stage treatment. Unlike most AI use cases that struggle to connect to a P&L, this one has a direct line to quality performance and shared-savings outcomes. The finding you connect is the same finding your contract is scored on.

So why is nobody building seriously for it?

Because it's not exciting. It doesn't demo well. It doesn't get a clinician to say "wow." But the connectivity problem underneath it — pulling the finding out of the right report, weighing it in context, surfacing it at the right workflow moment, and confirming the loop closed — is exactly the kind of unglamorous infrastructure work that determines whether AI in healthcare actually delivers.

The teams chasing the hard problems are solving for prestige. The teams that win value-based contracts will be solving for this.